
|Articles|August 15, 2004
Drug and prosthetic therapies for ED step forward
At the 2004 AUA annual meeting, researchers reported that daily administration of a phosphodiesterase type-5 inhibitor improves chances of recovery from post-prostatectomy erectile dysfunction-good news about a difficult-to-treat patient population. The bad news was a finding that herbal ED treatments purchased over the Internet are often ineffective, potentially dangerous, and occasionally tainted with active, unlabeled PDE-5 inhibitors.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Study suggests potential diuretic effect with nadofaragene firadenovec
3
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
4
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
5











